A Multi-centre, Open-labelled, Randomized Controlled Trial Comparing Two Different Anticoagulation Strategies in High-risk Atrial Fibrillation and Stable Coronary Artery Disease
Phase of Trial: Phase III
Latest Information Update: 24 Jul 2019
Price : $35 *
At a glance
- Drugs Edoxaban (Primary) ; Antiplatelets
- Indications Stroke; Thromboembolism
- Focus Adverse reactions; Therapeutic Use
- Acronyms EPIC-CAD
- 10 Jun 2019 Status changed from not yet recruiting to recruiting.
- 15 Apr 2019 Planned initiation date changed from 20 Apr 2019 to 30 Apr 2019.
- 12 Mar 2019 Planned initiation date changed from 20 Feb 2019 to 20 Apr 2019.